Treace Medical Concepts (TMCI) Cash & Equivalents (2020 - 2026)

Treace Medical Concepts' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $9.5 million for Q1 2026.

• Quarterly Cash & Equivalents fell 28.63% year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 million (down 28.63% YoY) and the FY2025 annual result came in at $10.7 million, down 5.66% from the prior year.
• Cash & Equivalents was $9.5 million for Q1 2026 at Treace Medical Concepts, down from $10.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $101.5 million in Q2 2022 and bottomed at $7.3 million in Q3 2023.
• A 5-year average of $23.9 million and a median of $12.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 507.25% — and 2023, when it plunged 88.15%.
• Treace Medical Concepts' Cash & Equivalents stood at $19.5 million in 2022, then slumped by 33.33% to $13.0 million in 2023, then dropped by 12.57% to $11.4 million in 2024, then fell by 5.66% to $10.7 million in 2025, then declined by 10.87% to $9.5 million in 2026.
• Business Quant data shows TMCI's Cash & Equivalents at $9.5 million in Q1 2026, $10.7 million in Q4 2025, and $7.7 million in Q3 2025.